**Hepatitis C Virus (HCV) NS5A Drug Resistance by Sequencing**

ARUP test code 2014139

**NS5A Genotype**

1a

**INTERPRETIVE INFORMATION: HCV NS5A Drug Resistance by Sequencing**

This assay detects resistance-associated variants in NS5A codons 20-101 for HCV genotypes 1a and 1b. Variants in viral sub-populations below 20 percent of total may not be detected. For further information, please refer to drug package inserts for the applicable direct acting antiviral drug and current HCV treatment guidelines (e.g., AASLD/IDSA guidelines or EASL HCV treatment recommendations).

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**NS5A Resistance**

See Note

---

**H=High, L=Low, *=Abnormal, C=Critical**
The following resistance-associated variants were identified:

None

Ledipasvir Resistance: Not Predicted
Elbasvir Resistance: Not Predicted
Ombitasvir Resistance: Not Predicted
Daclatasvir Resistance: Not Predicted
Velpatasvir Resistance: Not Predicted
Pibrentasvir Resistance: Not Predicted

A result of Predicted resistance indicates that one or more resistance-associated variant (RAV) was detected. These RAVs have been known to confer varying levels of resistance to treatment regimens containing the NS5A inhibitors ledipasvir or elbasvir. Resistance and interpretation for these variants is reported based on current EASL HCV treatment guidelines (available: http://www.easl.eu/research/our-contributions/clinical-practice-guidelines).

A result of Possible resistance indicates that one or more resistance-associated variant (RAV) was detected. Current guidelines and in vitro and/or clinical studies have identified these variants as having a possible association with resistance but may require additional studies to confirm. Please refer to the individual Direct Acting Antiviral (DAA) package inserts for additional treatment implications and guidance.

A result of Not Predicted resistance indicates that no RAVs were detected and/or variants detected have uncertain or no impact on response to DAA treatment. Additionally, variants in viral sub-populations below 20 percent of total may not be detected.

END OF CHART